ETFChannel.com
SWTX Description — SpringWorks Therapeutics Inc

SpringWorks Therapeutics a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing medicines for underserved patient populations suffering from devastating rare diseases and cancer. Co.'s product candidate, nirogacestat, is an oral, small molecule gamma secretase inhibitor for the treatment of desmoid tumors, a rare and often debilitating and disfiguring soft tissue tumor. Co.'s second product candidate is mirdametinib, an oral, small molecule MEK inhibitor for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, a rare tumor of the peripheral nerve sheath that causes pain and disfigurement.

Company Name: 
SpringWorks Therapeutics Inc
Website: 
www.springworkstx.com
Sector: 
Biotechnology
Number of ETFs Holding SWTX: 
28
Total Market Value Held by ETFs: 
$327,724,564.33
Total Market Capitalization: 
$3,544,000,000
% of Market Cap. Held by ETFs: 
9.25%
 ETF   SWTX Weight   SWTX Amount 
 VTI   0.00%   $60,242,489         
 VB   0.04%   $53,080,934         
 IWM   0.07%   $47,948,765         
 XBI   0.57%   $41,505,704         
 VBK   0.09%   $33,489,065         
 VXF   0.02%   $28,735,470         
 IBB   0.19%   $21,123,970         
 IWO   0.14%   $17,097,627         
 IDNA   1.61%   $5,994,564         
 VTWO   0.07%   $4,693,226         
List of all 28 ETFs holding SWTX »
Quotes delayed 20 minutes

Strong Buy (4.00 out of 4)
76th percentile
(ranked higher than approx. 76% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com

ETFs Holding SWTX | SpringWorks Therapeutics Inc | ETF Channel | www.ETFChannel.com

Copyright © 2010 - 2021, All Rights Reserved Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.